Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pralay Mukhopadhyay

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
JAMA Oncology|May 1, 2020
Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With CancerSerban Ghiorghiu, Pralay Mukhopadhyay, Cristian Massacesi
JAMA Oncology|February 9, 2023
The MaxCombo Test Severely Violates the Type I Error Rate-ReplyPralay Mukhopadhyay, Satrajit Roychoudhury, Keaven M Anderson
Clinical Trials (London, England)|August 31, 2024
15th Annual University of Pennsylvania conference on statistical issues in clinical trial/advances in time to event analyses in clinical trials (morning panel discussion)Pralay Mukhopadhyay, Douglas Schaubel, Mei-Cheng Wang
AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science|August 30, 2021
SAEgnal: A Predictive Assessment Framework for Optimizing Safety Profiles in Immuno-Oncology Combination TrialsAndrzej Prokop, Youyi Zhang, Pralay Mukhopadhyay, et al.
Clinical Pharmacology and Therapeutics|June 22, 2020
Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-AnalysisJiabu Ye, Xiang Ji, Phillip A Dennis, et al.
Journal of Biopharmaceutical Statistics|March 12, 2021
Statistical and practical considerations in designing of immuno-oncology trialsPralay Mukhopadhyay, Wenmei Huang, Paul Metcalfe, et al.
Pharmacoeconomics|May 19, 2019
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival ExtrapolationsMario J N M Ouwens, Pralay Mukhopadhyay, Yiduo Zhang, et al.
Current Therapeutic Research, Clinical and Experimental|September 6, 2021
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC StudyMario Ouwens, Annie Darilay, Yiduo Zhang, et al.
JAMA Oncology|July 21, 2022
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysisPralay Mukhopadhyay, Jiabu Ye, Keaven M Anderson, et al.
Oncology Research and Treatment|March 21, 2015
Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial dataShannon Cartier, Bin Zhang, Virginia M Rosen, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
JAMA Oncology|May 1, 2020
Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With CancerSerban Ghiorghiu, Pralay Mukhopadhyay, Cristian Massacesi
JAMA Oncology|February 9, 2023
The MaxCombo Test Severely Violates the Type I Error Rate-ReplyPralay Mukhopadhyay, Satrajit Roychoudhury, Keaven M Anderson
Clinical Trials (London, England)|August 31, 2024
15th Annual University of Pennsylvania conference on statistical issues in clinical trial/advances in time to event analyses in clinical trials (morning panel discussion)Pralay Mukhopadhyay, Douglas Schaubel, Mei-Cheng Wang
AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science|August 30, 2021
SAEgnal: A Predictive Assessment Framework for Optimizing Safety Profiles in Immuno-Oncology Combination TrialsAndrzej Prokop, Youyi Zhang, Pralay Mukhopadhyay, et al.
Clinical Pharmacology and Therapeutics|June 22, 2020
Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-AnalysisJiabu Ye, Xiang Ji, Phillip A Dennis, et al.
Journal of Biopharmaceutical Statistics|March 12, 2021
Statistical and practical considerations in designing of immuno-oncology trialsPralay Mukhopadhyay, Wenmei Huang, Paul Metcalfe, et al.
Pharmacoeconomics|May 19, 2019
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival ExtrapolationsMario J N M Ouwens, Pralay Mukhopadhyay, Yiduo Zhang, et al.
Current Therapeutic Research, Clinical and Experimental|September 6, 2021
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC StudyMario Ouwens, Annie Darilay, Yiduo Zhang, et al.
JAMA Oncology|July 21, 2022
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysisPralay Mukhopadhyay, Jiabu Ye, Keaven M Anderson, et al.
Oncology Research and Treatment|March 21, 2015
Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial dataShannon Cartier, Bin Zhang, Virginia M Rosen, et al.
Pageof 4